Human BioSystems (HBS) (OTCBB: HBSC), a developer of preservation platforms for organs and other biomaterials, specializing in the development of proprietary above zero (“HBS-AZ”) and below zero (“HBS-BZ”) organ and tissue preservation systems and methods for preserving blood platelets, announced a proposed offering of up to 10,500,000 shares of common stock by certain shareholders who obtained the stock in an earlier exchange offer pursuant to Regulation S promulgated under the Securities Act of 1933, as amended. HBS has filed with the Securities and Exchange Commission a registration statement relating to the proposed offering. HBS will not sell any shares of common stock in this offering, nor will it receive any proceeds from it.
